Report of the ECCO workshop on anti-TNF therapy failures in inflammatory bowel diseases: biological roles and effects of TNF and TNF antagonists.
This second section of the first ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases addresses the biological roles of TNFα and the effects and mechanisms of action of TNFα antagonists. Mechanisms underlying their failure, including induction of TNF-independent inflammatory pathways and phenomena of paradoxical inflammation are discussed.
Department of Gastroenterology, Rambam Health Care Campus, Haifa & Rappoport School of Medicine, Technion, Israel Institute of Technology, Israel.
Yehuda
Y
Chowers
Andreas
A
Sturm
Miquel
M
Sans
Konstantinos
K
Papadakis
Maria
M
Gazouli
Marcus
M
Harbord
Jörg
J
Jahnel
Gerassimos J
GJ
Mantzaris
Johannes
J
Meier
Christian
C
Mottet
Laurent
L
Peyrin-Biroulet
Matthieu
M
Allez
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D003424:Crohn Disease / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D016898:Interferon-alpha / Q000502:physiology; D020381:Interleukin-17 / Q000502:physiology; D053759:Interleukin-23 / Q000502:physiology; D051379:Mice; D055655:NK Cell Lectin-Like Receptor Subfamily K / Q000502:physiology; D017211:Treatment Failure; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000502:physiology
D000911:Antibodies, Monoclonal; D016898:Interferon-alpha; D020381:Interleukin-17; D053759:Interleukin-23; D055655:NK Cell Lectin-Like Receptor Subfamily K; D014409:Tumor Necrosis Factor-alpha